S&P 5007,659▼ 1.09%Nasdaq26,140▼ 2.15%Dow Jones52,002▼ 0.34%Nasdaq 10029,188▼ 2.50%VIX19.99▲ 21.45%US Dollar101.84▼ 0.21%Gold (GLD)382.01▼ 0.18%Oil (USO)161.76▲ 2.83%
Home › JPM › Research report
← JPM page
XStocksXray
Research report · 16 October 2026

Jpmorgan Chase & Co (JPM)

Financials · Diversified Banks · US stock · price as of 16 Oct 2026

Key indicators

Price$339.72
52-week range$275.06 – $364.68
Market cap$915.3B
P/E (trailing)14.3×
Dividend yield1.8%
Revenue (last 12 months)$183.1B
Revenue growth (3y a year)12.3%
Price / book2.4×
Return on equity17.4%

Fair value

Blended fair value$239.86 book-value models
Versus priceOvervalued−29% to fair value
Excess-return model (banks, insurers)$188.44
Price / book vs return on equity$316.98
Model uncertaintyHigh

X-Ray Score

51/ 100 · Medium confidence · ahead of 54% of sector peers
Valuation49
Growth50
Profitability54
Financial health48
Dividends58

Five-year price chart navy: price · brown: 200-day average · blue band: fair value range

76.68152228304380Fair value $2402021-102023-012024-042025-072026-10

Executive summary

JPMorgan Chase is one of the largest banking groups in the United States, with consumer banking, investment banking, commercial banking and asset and wealth management businesses. It earns net interest income on loans and deposits, fees for advising on deals and underwriting securities, trading revenue, and charges for managing client assets. It also runs a large credit card business, and its results are tied to interest rates and economic conditions.

Across three years the company recorded growth of 12.3% a year. Profitability shows a return on invested capital of 44%. Shareholders receive a dividend, currently yielding 1.8%.

StocksXray gives Jpmorgan Chase & Co an X-Ray Score of 51 out of 100 (medium confidence), ahead of 54% of the S&P 500 stocks in its sector. Its strongest lens is dividends (58) and its weakest is financial health (48).

Our fair value blend is $239.86. At $339.72 the stock trades 42% above that blend, so the label is "Overvalued" with high model uncertainty. Fair value is a range, not a price target.

stocksxray.com · page 1
XStocksXray
Jpmorgan Chase & Co (JPM)

Valuation history multiples at each fiscal year-end price; the last column uses today's price and the last twelve months

FY2021FY2022FY2023FY2024FY2025Now
Price$139.87$122.19$159.61$230.31$316.13$339.72
Market cap$423.3B$362.9B$469.7B$663.1B$879.3B$915.3B
P/E9.1×10.1×9.8×11.7×15.8×14.3×
Price / book1.4×1.2×1.4×1.9×2.4×2.4×
Dividend yield2.72%3.27%2.57%2.08%1.83%1.81%

Fundamentals checklist ● 4 Good · ● 0 Average · ● 3 Bad · each check graded against the sector

Risk models

Piotroski F-Score2 of 9Bad

Growth

EPS growth (3y)18.3%Good
Revenue growth (3y)12.3%Good
Growth consistency80%Bad

Valuation

Fair value vs price0.7×Bad

Profitability

Return on invested capital44.4%Good
Operating margin45.8%Good
stocksxray.com · page 2
XStocksXray
Jpmorgan Chase & Co (JPM)

Financials US$ millions, from SEC filings; last column is the last twelve months

Income statementFY21FY22FY23FY24FY25LTM
Revenue121,649128,695158,104177,556182,447183,077
Net income48,30037,70049,60058,50057,00065,019
Diluted EPS ($)15.3612.0916.2319.7520.0223.72
Net margin39.7%29.3%31.4%32.9%31.2%35.5%
Balance sheetFY21FY22FY23FY24FY25LTM
Total assets3,743,5673,665,7433,875,3934,002,8144,424,9005,015,069
Cash740,834567,234624,151469,317343,338309,811
Total debt53,59444,02744,71252,89364,77672,430
Equity294,127292,332327,878344,758362,438374,598
Dividend per share ($)3.804.004.104.805.806.00

Revenue and net income US$ billions: navy revenue, teal net income

FY21FY22FY23FY24FY25

Margins blue gross, teal operating, brown net

0%30%60%90%FY21FY22FY23FY24FY25

Latest quarters

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ($M)829901990179,7271,1531,207
Growth vs a year earlier+23.4%+30.8%+40.2%+2.4%+39.1%+34.0%
Net income ($M)14,64314,98714,39312,97716,49421,155
Diluted EPS ($)5.075.245.07–5.947.70
stocksxray.com · page 3
XStocksXray
Jpmorgan Chase & Co (JPM)

Peers in Diversified Banks

CompanyX-Ray
JPM · Jpmorgan Chase & Co51
USB · Us Bancorp De60
BAC · Bank Of America Corp48
PNC · Pnc Financial Services Gro...45
WFC · Wells Fargo & Company44

Market Compass outlook for Financials: Favourable (72/100). It blends regime history, macro sensitivity, momentum and valuation.

Returns

1 week+2.0%
1 month−2.3%
3 months+0.8%
6 months+10.5%
1 year+13.3%
3 years+147.7%
5 years+125.9%

Technical summary

DailyBullish9 bullish · 4 neutral · 3 bearish
WeeklyBullish7 bullish · 1 neutral · 4 bearish
MonthlyStrongly bullish7 bullish · 1 neutral · 0 bearish
50-day / 200-day average$346.69 / $319.46
52-week low / high$275.06 / $364.68
Classic pivot, support and resistanceS2 333.67 · S1 336.69 · P – · R1 343.57 · R2 347.43

Recent dividends

Ex-dividend dateAmount per share
6 Oct 2026$1.6500
6 Jul 2026$1.5000
6 Apr 2026$1.5000
6 Jan 2026$1.5000
6 Oct 2025$1.5000
3 Jul 2025$1.4000
stocksxray.com · page 4
XStocksXray
Jpmorgan Chase & Co (JPM)

Strengths

  • Return on invested capital of 44.4% is ahead of 91% of its sector peers.
  • Operating margin of 45.8% is ahead of 81% of its sector peers.
  • Revenue growth of 12.3% a year over three years is ahead of 79% of its sector peers.
  • Has raised its dividend for 7 years in a row.

Risks and weak spots

  • Piotroski F-Score is weak against Financials peers (2 of 9).
  • Growth consistency is weak against Financials peers (80%).
  • Fair value vs price is weak against Financials peers (0.7×).
  • The price is above our fair value range, so good news may already be in the price.

Latest SEC filings

DateFormItems
13 Oct 20268-K7.01,9.01
13 Oct 20268-K2.02,9.01
6 Aug 202610-Q
23 Jul 20268-K8.01,9.01
23 Jul 20268-K5.03
14 Jul 20268-K7.01,9.01
14 Jul 20268-K2.02,9.01
25 Jun 20268-K5.02

How to read this report

Every number comes from SEC filings, end-of-day prices and the StocksXray models described on the methodology page. The X-Ray Score ranks each metric against the company's own sector. Fair value blends three models and carries a typical error of about 40%, so treat it as a range. Analyst ratings, price targets and earnings-call summaries are not part of this report. Educational research, not financial advice; read the disclaimer.

stocksxray.com · page 5 · generated 19 Oct 2026